Indication Prioritization

At Evaluate, our mission is simple: to help patients gain access to life-saving therapies. Evaluate is a Norstella company, a collection of prominent pharmaceutical solutions providers that have joined forces to offer a full range of consultancy services and solutions. Evaluate provides life sciences clients with the right tools and expertise to navigate complexities at each step of the drug development life cycle, from pipeline to patient. Our offerings include cutting-edge data solutions, consensus forecasts and expert advisory services alongside advanced technologies such as machine learning and predictive analytics.

The Indication Prioritisation data product provides a comprehensive dataset for Indication Prioritization. It encompasses a wide range of data sources, offering valuable insights into various aspects of drug evaluation, clinical trials, and benchmarks. The scope of this dataset extends from historic drug approvals and launches to predicted approvals, providing a holistic view of the pharmaceutical landscape.

Indication prioritisation refers to the strategic process of selecting and ranking specific medical conditions or diseases that a drug or therapeutic intervention is intended to target. By prioritizing indications, pharmaceutical companies focus their resources and efforts on developing treatments that have the highest likelihood of success and impact on public health, ultimately guiding research and development strategies towards areas where they can make a significant difference.

The following sets of data have been included in this listing:

Drugs - Historic Approvals & Launches (indications): This table can provide insights into past trends in drug approvals and launches. It can help identify which indications have been prioritized in the past and may indicate areas of unmet need.

Drugs - Names and Identifiers: This table can be used to cross-reference drugs across different datasets using their names or unique identifiers.

Drugs - Classifications: This table provides information on how drugs are classified, which can be useful for understanding the types of drugs being developed for different indications.

Drugs - Sales by Indication (WW and US): This table provides data on drug sales by indication, which can help identify profitable indications and market trends.

Drugs - USA - NDC: The National Drug Code (NDC) table can be used to identify specific drugs in the US market.

Clinical trials - US basics: This table provides basic information about clinical trials in the US, which can be used to understand the landscape of ongoing research for different indications.

Drugs - Predicted approvals: This table provides forecasts of future drug approvals, which can help identify emerging indications of interest.

Clinical trials - Trial costs: This table provides data on the cost of clinical trials, which can be used to estimate the investment required for developing drugs for different indications.

Clinical trials - Dates: This table provides timelines of clinical trials, which can be used to track progress and estimate timelines for drug development.

Benchmarks - Indications: This table provides benchmark data for different indications, which can be used to compare the performance of drugs or trials against industry standards.

Clinical trials - EU basics and Clinical trials - Japan basics: These tables provide basic information about clinical trials in the EU and Japan, respectively. They can be used to understand the global landscape of research for different indications.

Drugs - NPV (indication): The Net Present Value (NPV) table provides an estimate of the potential profitability of drugs for different indications, which can be used to prioritize indications based on potential return on investment.

Indication-level treatment information: This table provides detailed information about treatments at the indication level, which can be used to understand current treatment paradigms and identify opportunities for new treatments.

You can use this data to analyze trends, make predictions, and inform your decision-making process in the pharmaceutical industry.

Once you subscribe to this listing, you will have access to all the data tables required.

Workflow:

• Consumer clicks Request button on Evaluate listing
• Evaluate will reach out to the consumer and finalize terms.
• Evaluate shares the data product with the consumer via Snowflake shares.

Additional Information
This data product is updated regularly to ensure that you have the most recent and accurate information. If you have any questions or need further information, please don’t hesitate to contact us.